Acrivon Therapeutics Reports Strong Clinical Data for ACR-368 in Endometrial Cancer and Promising ACR-2316 Phase 1 Results

summarizeSummary

Acrivon Therapeutics announced positive Phase 2b clinical data for ACR-368 in endometrial cancer, including high overall response rates in serous subtypes, and encouraging initial Phase 1 data for ACR-2316 in difficult-to-treat solid tumors. The company also nominated a new preclinical candidate, ACR-6840, and reported a cash runway into Q2 2027.

check_boxKey Events

• ACR-368 Phase 2b Data

  Reported a 67% overall response rate (ORR) in biomarker-positive serous endometrial cancer and 52% ORR in all-comer serous endometrial cancer, addressing a significant unmet need.

• ACR-368 Program Advancement

  Submitted Phase 3 trial design and protocol to the FDA for frontline treatment with ACR-368 + anti-PD-1, and expanded Phase 2b enrollment to EU sites.

• ACR-2316 Phase 1 Initial Data

  Demonstrated clinical activity with tumor shrinkage in 9 out of 20 evaluable patients, including in small cell lung cancer and squamous non-small cell lung cancer, with a favorable tolerability profile.

• New Preclinical Candidate

  Nominated ACR-6840, a potential first-in-class CDK11 inhibitor, with IND submission anticipated in Q4 2026, expanding the pipeline.

auto_awesomeAnalysis

This 8-K filing is highly significant for Acrivon Therapeutics, a life sciences company, as it provides substantial positive updates on its key clinical programs. The Phase 2b data for ACR-368 in endometrial cancer, particularly the 67% overall response rate in biomarker-positive serous endometrial cancer and 52% in all-comer serous endometrial cancer, is very compelling and addresses a high unmet medical need. This data significantly de-risks the ACR-368 program and outlines a clear path towards a registrational Phase 3 trial. Furthermore, the initial Phase 1 clinical data for ACR-2316 is promising, showing tumor shrinkage in challenging indications like small cell lung cancer and squamous non-small cell lung cancer, where other WEE1/PKMYT1 inhibitors have previously struggled. This suggests potential differentiation for ACR-2316. The nomination of ACR-6840 as a potential first-in-class CDK11 inhibitor further strengthens the company's pipeline, validating its AP3 platform. The reported cash runway into Q2 2027 provides financial stability to advance these programs. Investors should view these updates as a strong positive signal for the company's clinical development and future prospects.